XY Capital Ltd Invests $510,000 in argenex SE $ARGX

XY Capital Ltd bought a new position in shares of argenex SE (NASDAQ:ARGX) during the 4th quarter, HoldingsChannel reports. The institutional investor bought 606 shares of the company’s stock, valued at approximately $510,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Abound Wealth Management lifted its holdings in argenex by 3,200.0% during the fourth quarter. Abound Wealth Management now owns 33 shares of the company’s stock worth $28,000 after acquiring an additional 32 shares in the last quarter. Sound Income Strategies LLC acquired a new stake in shares of argenex in the 4th quarter valued at about $28,000. Ameriflex Group Inc. bought a new stake in argenex during the third quarter worth about $32,000. Sunbelt Securities Inc. bought a new stake in argenex during the third quarter worth about $36,000. Finally, Aventura Private Wealth LLC bought a new stake in argenex during the fourth quarter worth about $38,000. 60.32% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on ARGX. Zacks Research raised argenex from a “strong sell” rating to a “hold” rating in a research report on Friday, February 20th. Wells Fargo & Company boosted their price target on argenex from $1,260.00 to $1,291.00 and gave the stock an “overweight” rating in a research report on Monday, June 1st. Deutsche Bank Aktiengesellschaft raised argenex from a “hold” rating to a “buy” rating in a research report on Tuesday, March 10th. Guggenheim boosted their price target on argenex from $1,120.00 to $1,135.00 and gave the stock a “buy” rating in a research report on Friday, May 8th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $1,000.00 target price on shares of argenex in a research report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $1,019.50.

argenex Price Performance

NASDAQ ARGX opened at $898.94 on Friday. The business has a fifty day moving average price of $809.08 and a two-hundred day moving average price of $811.60. argenex SE has a fifty-two week low of $510.05 and a fifty-two week high of $934.62. The stock has a market capitalization of $55.91 billion, a PE ratio of 40.02, a PEG ratio of 1.32 and a beta of 0.47.

argenex (NASDAQ:ARGX) last released its earnings results on Tuesday, March 31st. The company reported $5.52 earnings per share for the quarter. argenex had a return on equity of 44.37% and a net margin of 31.31%.The firm had revenue of $1.31 billion during the quarter. As a group, sell-side analysts expect that argenex SE will post 26.19 earnings per share for the current year.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.